Companies · Biotechnology

TearSolutions, Inc.

Charlottesville · Biotechnology

Diligence memoA one-page analyst read on TearSolutions, Inc. — recommendation, valuation, rhythm, risks.
$39.5M
Total raised · real
11
Rounds
0.0×
Latest step-up
Top 23%
Sector rank · raised
Series A
Latest stage · inferred · Wed Oct 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

TearSolutions, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.09× the median modeled value of Series A Biotechnology companies in 2025–2027 (156 peers) — value vs value, same stage and era.
Active
  • Last raise 8 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

TearSolutions, Inc. is one of 4291 Biotechnology companies tracked from Charlottesville. By capital raised it ranks in the upper tier (ahead of 78% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
12
Investors (latest)
2025-10-29
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MPre-Seed · 2014-05-06 Raised $390K (real) Modeled valuation $22M (est)Pre-Seed2014Pre-Seed · 2014-10-30 Raised $500K (real) Modeled valuation $28M (est)Pre-Seed2014Seed · 2017-01-18 Raised $1.1M (real) Modeled valuation $48M (est)Seed2017Seed · 2017-01-18 Raised $3.4M (real) Modeled valuation $151M (est)Seed2017Series A · 2017-12-04 Raised $8.1M (real) Modeled valuation $291M (est)Series A2017Series A · 2019-03-04 Raised $4.0M (real) Modeled valuation $146M (est)Series A2019Series A · 2019-03-04 Raised $1.3M (real) Modeled valuation $48M (est)Series A2019Series A · 2019-03-04 Raised $5.1M (real) Modeled valuation $185M (est)Series A2019Pre-Seed · 2019-03-04 Raised $885K (real) Modeled valuation $49M (est)Pre-Seed2019Series A · 2020-02-12 Raised $1.5M (real) Modeled valuation $54M (est)Series A2020Series A · 2021-07-16 Raised $5.6M (real) Modeled valuation $123M (est)Series A2021Series A · 2023-09-08 Raised $390K (real) Modeled valuation $3.0M (est)Series A2023Series A · 2024-09-25 Raised $13M (real) Modeled valuation $60M (est)Series A2024Series A · 2025-10-29 Raised $517K (real) Modeled valuation $1.4M (est)Series A2025Cumulative $46M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$390K · 2014
Pre-Seed extension$500K · 2014
Seed$1.1M · 2017
Seed extension$3.4M · 2017
Series A$8.1M · 2017
Series A extension$4.0M · 2019
Series A extension$1.3M · 2019
Series A extension$5.1M · 2019
Bridge · Series A-stage$885K · 2019smaller follow-on
Series A extension$1.5M · 2020
Series A extension$5.6M · 2021
Series A extension$390K · 2023
Series A extension$12.7M · 2024
Series A extension$517K · 2025

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$1.4M
Base estimate est.
$564K
Conservative case
$2.3M
Upside case
$2.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $21.5M · 2014-05-062014Pre-Seed · modeled $27.6M · 2014-10-30Seed · modeled $48.0M · 2017-01-18Seed · modeled $151.4M · 2017-01-18Series A · modeled $291.3M · 2017-12-04Series A · modeled $146.2M · 2019-03-04Series A · modeled $48.2M · 2019-03-04Series A · modeled $185.0M · 2019-03-04Pre-Seed · modeled $48.9M · 2019-03-04Series A · modeled $54.2M · 2020-02-12Series A · modeled $123.0M · 2021-07-16Series A · modeled $3.0M · 2023-09-08Series A · modeled $59.5M · 2024-09-25Series A · modeled $1.4M · 2025-10-292025
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
0.7 yr
Elapsed time used
0.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
11 mo
Avg between rounds
$3.4M/yr
Capital velocity
12.2 yr
On record since
2014
First round
14
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 5.5× above median
This company$39.5M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.1× of median
This company$517K
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$1.4M
Sector median$64.2M

Raised more than 78% of sector peers (real $). Modeled value above 4% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #144 of 156.

This companyCohort peer
$1.0M$10.0M$100.0M$10.0M$100.0MCapital raised (log)Acasti Pharma Inc. · Series A Raised $23.0M · modeled $58.5M (est)Edesa Biotech, Inc. · Series A Raised $36.9M · modeled $58.4M (est)4DMedical Ltd · Series A Raised $15.0M · modeled $50.6M (est)Arialys Therapeutics, Inc. · Series A Raised $29.1M · modeled $49.1M (est)Nuclein, LLC · Series A Raised $34.5M · modeled $48.3M (est)Phantom Neuro Inc. · Series A Raised $15.4M · modeled $45.7M (est)Circulate Health, Inc. · Series A Raised $13.0M · modeled $43.2M (est)Biovantix Biotechnology, Inc · Series A Raised $15.0M · modeled $42.1M (est)Bariendo Inc. · Series A Raised $11.1M · modeled $40.9M (est)ENDRA Life Sciences Inc. · Series A Raised $26.8M · modeled $40.8M (est)Medici Therapeutics, Inc. · Series A Raised $14.8M · modeled $39.7M (est)Onconetix, Inc. · Series A Raised $22.0M · modeled $37.7M (est)TearSolutions, Inc. (this company) Raised $39.5M · modeled $1.4M (est)TearSolutions, Inc.
CompanyStageRaised · realValue · estvs peer med.
Acasti Pharma Inc.Series A$23.0M$58.5M3.76×
Edesa Biotech, Inc.Series A$36.9M$58.4M3.75×
4DMedical LtdSeries A$15.0M$50.6M3.25×
Arialys Therapeutics, Inc.Series A$29.1M$49.1M3.15×
Nuclein, LLCSeries A$34.5M$48.3M3.10×
Phantom Neuro Inc.Series A$15.4M$45.7M2.93×
Circulate Health, Inc.Series A$13.0M$43.2M2.77×
Biovantix Biotechnology, IncSeries A$15.0M$42.1M2.70×
Bariendo Inc.Series A$11.1M$40.9M2.62×
ENDRA Life Sciences Inc.Series A$26.8M$40.8M2.62×
Medici Therapeutics, Inc.Series A$14.8M$39.7M2.55×
Onconetix, Inc.Series A$22.0M$37.7M2.42×
TearSolutions, Inc. this companySeries A$39.5M$1.4M0.09×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$390K2014-05-06$2.2M$21.5M85%
Pre-Seed$500K2014-10-30$2.8M$27.6M85%
Seed$1.1M2017-01-18$5.4M$48.0M90%
Seed$3.4M2017-01-18$17.1M$151.4M90%
Series A$8.1M2017-12-04$36.6M$291.3M90%
Series A$4.0M2019-03-04$18.4M$146.2M90%
Series A$1.3M2019-03-04$6.1M$48.2M90%
Series A$5.1M2019-03-04$23.3M$185.0M90%
Pre-Seed$885K2019-03-04$4.9M$48.9M90%
Series A$1.5M2020-02-12$6.8M$54.2M90%
Series A$5.6M2021-07-16$25.6M$123.0M90%
Series A$390K2023-09-08$1.8M$3.0M90%
Series A$12.7M2024-09-25$57.8M$59.5M90%
Series A$517K2025-10-29$2.4M$1.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$390K2014-05-06
    • First recorded raise — entered as Pre-Seed.
    • 5 investors on this round.
  2. Pre-Seed$500K2014-10-30
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  3. Seed$1.1M2017-01-18
    • Raised again after 27 mo — slower than the ~14 mo sector norm.
    • Round 2.2× larger than the prior — scaling up.
    • 12 investors on this round.
  4. Seed$3.4M2017-01-18
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.2× larger than the prior — scaling up.
    • 22 investors on this round.
  5. Series A$8.1M2017-12-04
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
    • 24 investors on this round.
  6. Series A$4.0M2019-03-04
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 19 investors on this round.
  7. Series A$1.3M2019-03-04
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.0× smaller than the prior — bridge or down round.
    • 16 investors on this round.
  8. Series A$5.1M2019-03-04
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.8× larger than the prior — scaling up.
    • 22 investors on this round.
  9. Pre-Seed$885K2019-03-04
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.8× smaller than the prior — bridge or down round.
    • 13 investors on this round.
  10. Series A$1.5M2020-02-12
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
    • 36 investors on this round.
  11. Series A$5.6M2021-07-16
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 3.8× larger than the prior — scaling up.
    • 44 investors on this round.
  12. Series A$390K2023-09-08
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 14.4× smaller than the prior — bridge or down round.
    • 10 investors on this round.
  13. Series A$12.7M2024-09-25
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 32.6× larger than the prior — scaling up.
    • 80 investors on this round.
  14. Series A$517K2025-10-29
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 24.6× smaller than the prior — bridge or down round.
    • 12 investors on this round.
Intelligence
2026 ~Q3
Modeled next raise · ~11mo cadence
$517K
Modeled next size est.range $517K$827K
0.0×
Last step-up
$3.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
John Moore11 other2019-03
Konstantine Drakonakis7 other2017-01
Thomas Gadek2 other2017-01
Alexey Vinogradov1 other2017-12
Colin M. Rolph1 other2014-05
Marc Odrich1 other2019-03
Michelle Carpenter1 other2019-03
Tom Gadek1 other2017-12
William McIlwaine Thompson, Jr.1 other2019-03
W. McIlwaine Thompson, Jr.1 other2017-12
Alexey McIlwaine Vinogradov2019-03
Alexey P. Chernushkin2021-07
Amir M Shojaei2023-09
Amir W Shojaei2025-10
Anil B. Asrani2021-07
Anil M Asrani2023-09
Anil W Asrani2025-10
Bruce Kuper2017-01
Bruce Kupper2017-12
Bruce P. Kupper2021-07
Colin Rolph2017-01
Gordon Laurie2017-01
Gordon W. Laurie2014-05
James M Ramey2023-09
Registry & provenance

TearSolutions, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1611687
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Biorez, Inc.BiotechnologySeries A$25.0M$89.0Mnetwork1 shared operator · same sector · same stage
Hemoshear Therapeutics, LlcBiotechnologySeries B$8.8M$90.5Mnetwork2 shared operators · same sector
Xenetic Biosciences, Inc.BiotechnologySeries A$17.6M$5.9Mnetwork1 shared operator · same sector · same stage
Liberate Medical, Inc.BiotechnologySeries A$5.9M$13.6Mnetwork1 shared operator · same sector · same stage
Ariel Precision Medicine, Inc.BiotechnologySeries A$5.4M$190.5Mnetwork1 shared operator · same sector · same stage
Biostage, Inc.BiotechnologySeries A$36.5M$1.8Msame sector · same stage
Trethera CorpBiotechnologySeries A$35.1M$880Ksame sector · same stage
MCAL Therapeutics Inc.PharmaSeries A$6.3M$34.7Mnetwork2 shared operators · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
BioSolution Designs, Inc.BiotechnologyPre-Seed$1.1M86%
Urolution Medical Inc.BiotechnologyPre-Seed$852K86%
Cellsolutions LlcBiotechnologyPre-Seed$49.7M85%
Tissuetech, Inc.BiotechnologySeries C$2.3B85%
CryOSA, Inc.BiotechnologySeries A$19.4M84%
BlueWillow Biologics, Inc.BiotechnologySeries A$5.5M84%
Pulse Biosciences, Inc.BiotechnologySeries C$1.4B84%
Emergent BioSolutions Inc.BiotechnologySeries C$2.0B84%
Frequently asked
How much funding has TearSolutions, Inc. raised?
TearSolutions, Inc. has raised approximately $39.5M in disclosed capital across 11 recorded financing rounds, aggregated from public filings.
What is TearSolutions, Inc.'s estimated valuation?
Provath's modeled valuation for TearSolutions, Inc. is approximately $1.4M (modeled range $564K–$2.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is TearSolutions, Inc. at?
TearSolutions, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Oct 29.
What does TearSolutions, Inc. do and where is it based?
TearSolutions, Inc. operates in the Biotechnology sector, based in Charlottesville.
Explore related

See where TearSolutions, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at TearSolutions, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.